How to Choose Independent Non-Executive Directors for a US Listing: Balancing Diversity and Expertise

The SEC’s final rules on universal proxy cards, effective since September 2022, have fundamentally altered the calculus for director elections at US-listed companies, but a more consequential shift is unfolding in 2025-2026: the SEC Division of Corporation Finance is now applying heightened scrutiny to board composition disclosures under Item 407 of Regulation S-K, specifically targeting the independence and expertise narratives in proxy statements for foreign private issuers (FPIs). Concurrently, the Nasdaq Stock Market’s 2023 board diversity rule, requiring at least two diverse directors or a public explanation for non-compliance, is facing legal challenges in the Fifth Circuit (Alliance for Fair Board Recruitment v. SEC, 2024), creating a compliance dilemma for Hong Kong and PRC-based FPIs that must simultaneously satisfy both US exchange mandates and the Hong Kong Stock Exchange’s (HKEX) own Listing Rules on board independence under Chapter 3 and Appendix 14. For a company pursuing a US listing via a traditional IPO on the NYSE or a de-SPAC transaction, the selection of independent non-executive directors (INEDs) is no longer a compliance checkbox—it is a risk-management decision that directly impacts SEC review timelines, shareholder litigation exposure, and the ability to secure institutional investor support. This article dissects the regulatory framework, quantifies the trade-offs between diversity mandates and sector-specific expertise, and provides a structured methodology for constructing a board that passes SEC scrutiny without sacrificing operational relevance.

The Regulatory Scaffold: US Exchange Rules vs. HKEX Standards

Nasdaq’s Diversity Rule and the Fifth Circuit Uncertainty

The Nasdaq Board Diversity Rule (Listing Rule 5605(f)), which became effective for all listed companies on August 7, 2023, requires each listed company to have, or explain why it does not have, at least two diverse directors, including one who self-identifies as female and one who self-identifies as an underrepresented minority or LGBTQ+. For FPIs, the rule permits compliance through a “foreign issuer alternative” that allows the board to meet diversity requirements based on the company’s home country legal framework, but this exemption is narrow and requires a formal board resolution. As of Q1 2025, approximately 14% of Nasdaq-listed FPIs from the Asia-Pacific region have filed diversity matrix disclosures under Listing Rule 5605(f)(2), according to data compiled by the Nasdaq Listing Services team. The legal challenge in Alliance for Fair Board Recruitment v. SEC (No. 23-60287, 5th Cir.), filed in June 2023 and argued in November 2024, contests the SEC’s approval of the rule on constitutional grounds, with a decision expected in mid-2025. If the rule is struck down, Nasdaq-listed companies—including Hong Kong issuers—would lose a clear compliance baseline, reverting to the general NYSE standard that requires only a majority independent board under Section 303A.01 of the NYSE Listed Company Manual. This regulatory uncertainty compels FPIs to design a board that can withstand either outcome: over-indexing on diversity to meet the Nasdaq rule risks creating a board heavy on non-sector expertise, while under-indexing risks a listing delay or a “comply-or-explain” deficiency that institutional investors penalize.

HKEX’s Stricter Independence Tests Under Chapter 3

Hong Kong issuers listing in the US must reconcile Nasdaq/NYSE rules with HKEX Listing Rules, which impose more granular independence criteria. Under HKEX Rule 3.13, the exchange evaluates independence based on nine specific factors, including any past or present financial interest in the issuer exceeding 1% of total share capital, any business relationship with the issuer in the preceding three years, and any family ties to substantial shareholders. The HKEX’s 2024 consultation paper on board effectiveness (published in November 2024) proposed tightening the “cooling-off period” for former professional advisers (auditors, lawyers, sponsors) from three to five years before they can be deemed independent—a change that would directly affect US-listed FPIs that also maintain a Hong Kong listing or have HKEX as a secondary listing venue. For a company structured as a Cayman Islands exempted company with a Hong Kong trading desk, the INED must satisfy both the US “no material relationship” test under NYSE Section 303A.02(b) and the HKEX’s specific prohibitions. Data from the HKEX’s 2024 Annual Corporate Governance Report indicates that 67% of listed issuers on the Main Board have at least one INED who previously served as a professional adviser to the group within the last three years—a practice that would become non-compliant under the proposed HKEX amendments. A US-listed FPI that ignores this divergence risks a dual regulatory failure: an SEC comment letter on independence disclosures and a HKEX reprimand under Listing Rule 2A.09.

The Expertise-Diversity Trade-Off: Quantifying the Cost of Mismatch

Sector Expertise as a Risk Mitigation Tool

For a US-listed company in the technology or biotech sector, the SEC’s focus on financial expertise under Item 407(d)(5) of Regulation S-K requires at least one “audit committee financial expert” (ACFE) who has direct experience in accounting, auditing, or financial oversight. The SEC’s 2023 Staff Report on the Implementation of the ACFE Rule found that 94% of FPIs with a market cap above USD 1 billion appointed an ACFE who was also the CEO or CFO of another public company—a profile that typically comes from the same industry. For a Hong Kong-based fintech issuer listing on the Nasdaq, the optimal INED candidate is a former CFO of a comparable fintech firm who also holds a CPA (US) or HKICPA qualification. This individual brings two distinct advantages: first, the ability to challenge management’s revenue recognition policies under ASC 606 (Revenue from Contracts with Customers), which is a common SEC comment letter trigger for subscription-based business models; second, the credibility to negotiate with the SEC’s Office of the Chief Accountant on complex technical issues. The cost of a mismatch is measurable: a study by the Stanford Rock Center for Corporate Governance (2024) found that companies that appointed an ACFE without sector-specific experience faced an average of 2.7 additional SEC comment letter rounds, adding 34 days to the IPO registration process.

Diversity Mandates and the “Overlap Problem”

The Nasdaq diversity rule creates a structural tension when applied to sectors with shallow talent pools. In the biotech sector, for example, the number of female directors with PhDs in molecular biology and prior CEO experience at a publicly traded biotech firm is estimated at fewer than 120 globally, according to a 2024 analysis by the Biotechnology Innovation Organization (BIO). A Hong Kong-based biotech issuer listing on the Nasdaq must find a director who is simultaneously female (to meet the gender diversity requirement), independent under both US and HKEX rules, and has the scientific credibility to serve on the compensation committee—a triple constraint that often forces the company to choose between a candidate with strong diversity credentials but limited biotech experience, or a sector expert who does not meet the diversity threshold. The SEC’s 2024 review of proxy statements for FPIs in the healthcare sector revealed that 31% of filers included a director whose primary qualification was “diversity” rather than “industry expertise,” a category that the SEC has flagged as potentially misleading under the anti-fraud provisions of Rule 10b-5. The solution is to broaden the search to adjacent sectors: a female director with a PhD in chemical engineering and experience at a large pharmaceutical company may not have direct biotech CEO experience, but her background in regulatory affairs and FDA submission processes provides sufficient sector adjacency to satisfy both the expertise requirement and the diversity mandate.

Structuring the Board for a De-SPAC Transaction

The SPAC Board Conversion Challenge

In a de-SPAC transaction, the target company must replace the SPAC’s pre-existing board—which typically consists of the SPAC sponsor and its affiliates—with a new board that meets the listing exchange’s independence requirements within 90 days of the business combination closing, as specified under Nasdaq Listing Rule 5605(b)(1)(A). This compressed timeline creates a specific risk: the SPAC sponsor often retains the right to nominate directors under the terms of the sponsor support agreement, but those nominees may not meet the independence criteria under the exchange rules or the SEC’s definition of “independent director” under Rule 10A-3 (which requires that the audit committee consist solely of independent directors). For a Hong Kong-based target company, the situation is further complicated by the HKEX’s requirement under Rule 3.10 that the board must comprise at least three INEDs, and under Rule 3.21 that the audit committee must have a minimum of three members, all of whom must be independent. A de-SPAC transaction involving a BVI-incorporated target and a Cayman SPAC must therefore identify at least three INEDs who satisfy both US and HKEX independence tests simultaneously—a pool that is narrower than either jurisdiction’s standard alone. Data from the SPAC Research Institute (Q1 2025) indicates that 22% of de-SPAC transactions completed in 2024 experienced a board composition deficiency that required a cure period under Nasdaq rules, with an average delay of 47 days to the listing date.

The “Independent Chair” Requirement as a Structural Constraint

Nasdaq Listing Rule 5605(b)(2) requires that independent directors hold regularly scheduled executive sessions without management, but does not mandate an independent board chair. However, the HKEX’s Code Provision A.2.1 under Appendix 14 recommends that the roles of chairman and CEO be separate and not held by the same individual, and if they are combined, the company must appoint an independent deputy chairman. For a US-listed FPI that is also HKEX-listed, the stricter HKEX standard effectively overrides the Nasdaq flexibility. The practical consequence is that the INED pool must include a candidate capable of serving as independent chair or lead independent director, which imposes additional requirements: the candidate must have prior board chair experience, must not have served on the board for more than nine years (under HKEX Rule 3.13’s “long service” factor), and must not be a representative of any substantial shareholder. For a family-controlled Hong Kong issuer listing in the US, the independent chair role is particularly sensitive because it requires a director who can credibly oppose the founder-CEO on matters of related-party transactions and executive compensation—a dynamic that is structurally difficult to achieve if the INED is selected from the founder’s personal network. The SEC’s 2024 Staff Guidance on Related Party Transactions (Release No. 33-11287) explicitly warns that “independence is not merely a formal status but a functional reality,” and the SEC will review the board’s actual decision-making record, not just the director’s biography.

Practical Selection Criteria and Disclosure Strategy

The “Three-Test” Framework for INED Selection

Based on the regulatory requirements and market practices observed in 2024-2025, a systematic approach to INED selection for a US listing involves three sequential tests. Test 1: Jurisdictional Independence. The candidate must pass both the US independence test under NYSE Section 303A.02 (no material relationship with the company, its affiliates, or its auditors) and the HKEX’s nine-factor test under Rule 3.13. This requires a formal independence assessment using a questionnaire that covers the candidate’s personal and business relationships for the preceding five years, not three. Test 2: Functional Fit. The candidate must fill a specific committee need—audit committee financial expert, compensation committee member with human capital management experience, or nominating committee member with governance expertise. The SEC’s 2024 comment letter trends show that 43% of FPIs received a comment on the “qualifications of directors” section of the proxy statement, with the SEC specifically asking how a director’s experience “qualifies them to serve in the specific committee role.” Test 3: Diversity Compliance. The candidate must contribute to the company’s diversity matrix under Nasdaq Rule 5605(f)(2) or provide a credible “explain” rationale. For companies that cannot find a candidate who passes all three tests, the optimal strategy is to expand the board size by one seat rather than compromise on any single test—a move that adds approximately USD 80,000-120,000 in annual director compensation costs but avoids the regulatory delay and reputational risk of a deficient board.

Disclosure as a Defensive Tool

The proxy statement’s “Director Qualifications” section should not merely list degrees and prior roles; it must explicitly map each INED’s experience to the specific regulatory requirements. For example, instead of stating “Ms. Chan has 20 years of experience in the technology sector,” the disclosure should read: “Ms. Chan’s service as CFO of Company X (a NYSE-listed technology firm) from 2015 to 2023, combined with her CPA (US) certification, qualifies her as an audit committee financial expert under Item 407(d)(5) of Regulation S-K, and her independence is confirmed under NYSE Section 303A.02(b) and HKEX Rule 3.13 based on the absence of any material relationship as defined in those rules.” This level of specificity serves two purposes: it preempts SEC staff questions by providing the regulatory rationale inline, and it creates a documented record that can be used to defend against shareholder derivative lawsuits alleging that the board was not properly constituted. The 2024 Delaware Court of Chancery decision in In re Lordstown Motors Corp. Stockholder Litigation (C.A. No. 2024-0123) held that a board’s failure to disclose the specific independence analysis in the proxy statement constituted a breach of fiduciary duty, even though the directors were technically independent under the exchange rules.

Actionable Takeaways

1. Conduct a formal independence assessment using a five-year lookback period (not three) for any candidate who has had a prior professional or business relationship with the issuer, its sponsors, or its auditors, to simultaneously satisfy US exchange rules and the proposed HKEX cooling-off amendment.
2. Prioritize the audit committee financial expert role as the first INED appointment, because the SEC’s 2024 comment letter data shows that ACFE qualifications are the most frequently challenged disclosure item for FPIs, and a deficiency here can delay the SEC’s effectiveness declaration by 3-6 weeks.
3. For de-SPAC transactions, identify the three independent directors required for the post-closing board at the letter-of-intent stage, not after the business combination agreement is signed, because the 90-day cure period under Nasdaq Rule 5605(b)(1)(A) is insufficient to recruit qualified candidates in the Asia-Pacific talent market.
4. Structure the board to have at least one INED with direct regulatory experience in the target company’s home jurisdiction (e.g., a former SFC or CSRC official), because the SEC’s 2024 cross-border enforcement priorities specifically target FPIs with weak local regulatory compliance oversight.
5. Draft the proxy statement’s director qualifications section as a regulatory compliance document, not a marketing biography, by explicitly citing the specific exchange rule and SEC regulation that each director’s experience satisfies, and file a draft with SEC staff for informal review before the formal proxy filing.